Anti-HER2 therapies have been demonstrated to have promising efficacy against HER2-positive breast cancers; however, the benefits of such a treatment have not yet been translated to those tumors that do not have HER2 overexpression [2]. The gene discussed is ERBB2; the disease is breast carcinoma.